James S. Wysock, MD, MSc

James S. Wysock, MD, MSc

NYU Grossman School of Medicine

New York, New York

James S. Wysock, MD, MSc, is a Clinical Assistant Professor of Urology at New York University Grossman School of Medicine in New York, New York. Dr. Wysock also serves as the Division Chief of Urology at Bellevue Hospital Center in New York City. His research focuses on advanced imaging techniques and treatment tools to optimize cancer diagnostics and therapy. Dr. Wysock’s clinical research efforts focus on image-guided prostate cancer diagnosis and treatment, including MRI-US fusion biopsy and partial gland prostate ablation techniques, and his specialization in urologic oncology includes cancers of the kidneys, bladder, ureters, testes, and prostate.

Dr. Wysock earned his undergraduate degree in Chemical Engineering from the University of Illinois at Urbana-Champaign and his medical degree from Northwestern University's Feinberg School of Medicine in Chicago, Illinois. He completed his internship and residency training in urology at New York-Presbyterian Hospital in New York City. Dr. Wysock then completed his fellowship in Urologic Oncology and Robotic Surgery at New York University, where he also obtained a Master’s of Clinical Investigation.

Talks by James S. Wysock, MD, MSc

Role of Whole Gland Ablation in Prostate Cancer

Role of Whole Gland Ablation in Prostate Cancer

| Apr 2025

James Wysock, MD, MS, delves into the evolving role of whole gland ablation (WGA) in prostate cancer management, particularly in intermediate- to high-risk cases and challenging clinical scenarios.

In this 20-minute presentation, Dr. Wysock highlights specific patient profiles where WGA may be preferable, including those with prior pelvic radiation, contraindications to surgery or radiotherapy, or elderly patients seeking less invasive yet effective treatment. In the salvage setting, WGA offers a compelling alternative for local recurrences, achieving substantial cancer control while avoiding aggressive surgical or radiation options.

Technological advancements like TULSA and HIFU enhance WGA precision. Challenges such as recurrence rates and in-field failures underscore the need for meticulous treatment planning and expanded ablation margins.

Dr. Wysock advocates for trials to validate WGA as a mainstream option, particularly in patients who cannot undergo radical treatments. This approach aligns with evolving guidelines and patient preferences, underscoring WGA’s potential as a transformative option in prostate cancer care.

Read More
PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and Margins

PSMA PET for Preoperative Planning of Prostate Cancer: Nodes, Nerves and Margins

| Dec 2024

James Wysock, MD, MS, highlights the transformative role of novel imaging techniques, particularly PSMA PET and MRI, in improving prostate cancer diagnosis, staging, and management.

In this 14-minute presentation, Dr. Wysock explains the combination of PSMA PET and MRI significantly improves the detection of extraprostatic extension and seminal vesicle invasion compared to conventional imaging.

Meta-analyses confirm PSMA PET’s superior accuracy, particularly its high negative predictive value. This suggests that some intermediate-risk men with negative scans might safely omit extended lymph node dissection. This evidence raises important discussions about refining surgical planning and patient consent to balance risks and outcomes.

Wysock addresses emerging data supporting direct prostatectomy based on highly suspicious PSMA PET findings, bypassing biopsies. While controversial, this approach underscores the potential for imaging advancements to redefine standard workflows, especially as artificial intelligence enhances interpretation and decision-making.

Dr. Wysock emphasizes that while PSMA PET and MRI improve staging and management, these tools are still primarily validated in high-risk populations, with sensitivity challenges in lower-risk groups. The evolving role of advanced imaging, coupled with ongoing technological progress, promises to reshape prostate cancer treatment pathways.

Read More
The Application of Stimulated Raman Histology to Urologic Malignancies – Human and Artificial Intelligent Assessment

The Application of Stimulated Raman Histology to Urologic Malignancies – Human and Artificial Intelligent Assessment

| Aug 2024

James S. Wysock, MD, MSc, explores Stimulated Raman Histology (SRH) in diagnosing and managing urologic malignancies, emphasizing the role of both human and artificial intelligence (AI) assessments. SRH, a cutting-edge imaging technique, provides rapid, label-free histological images of tissues, enabling real-time intraoperative diagnosis. Dr. Wysock highlights SRH’s high specificity and sensitivity in identifying cancerous tissues, potentially reducing reliance on frozen sections and improving surgical outcomes.

Dr. Wysock discusses integrating AI into SRH image analysis, including creating training datasets, validation studies, and clinical trials. The potential for AI to enhance diagnostic precision and minimize human error is a key focus. Data show that SRH, combined with AI assessment, significantly improves the accuracy of margin detection during prostate and kidney cancer surgeries.

Read More